(Q40090889)

17 September 2017

1 reference

title

Drug therapy of inflammatory bowel disease (English)

1 reference

17 September 2017

Drug Therapy of Inflammatory Bowel Disease (English)

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

inflammatory bowel diseases

12 August 2023

main subject

0 references

author name string

D. M. Sack

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6136027

12 August 2023

M. A. Peppercorn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6136027

12 August 2023

language of work or name

English

0 references

publication date

1 May 1983

1 reference

full work available at URL

17 September 2017

http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1875-9114.1983.tb03245.x

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1875-9114.1983.tb03245.x

12 August 2023

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

12 August 2023

1 reference

17 September 2017

3

1 reference

17 September 2017

3

1 reference

17 September 2017

158-176

1 reference

Recent developments in "nonspecific" inflammatory bowel disease (first of two parts).

17 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Salicylazosulfapyridine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Drug therapy: Sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Further experience in the treatment of severe attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Short-term course and prognosis of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and mucosal cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Placental and mammary transfer of sulphasalazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Ulcerative colitis and pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Sulphasalazine and male infertility: reversibility and possible mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

An experiment to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

The therapeutic effect of methyl-salazosulphapyridine versus salazosulphapyridine in active ulcerative colitis. A double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Prostaglandin synthesis inhibitors in ulcerative colitis: Flurbiprofen compared with conventional treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Inhibition of Folate Enzymes by Sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Inhibition of leucocyte motility and prevention of immune-complex experimental colitis by hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Cortisone and corticotrophin in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Treatment of toxic megacolon a comparative review of 29 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

A Controlled Comparison of Corticotropin and Hydrocortisone in the Treatment of Severe Proctocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

A Comparison of Oral Prednisolone Given as Single or Multiple Daily Doses for Active Proctocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

URINARY EXCRETION OF PREDNISOLONE AFTER INTRARECTAL THERAPY IN ULCERATIVE COLITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Adrenal cortical and pituitary function after intrarectal steroid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Prednisolone absorption in acute colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Rectally administered prednisolone--evidence for a predominantly local action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Effect of prednisolone on prostaglandin synthesis by rectal mucosa in ulcerative colitis: investigation by laminar flow bioassay and radioimmunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Low dose steroids and clinical relapse in Crohn's disease: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Controlled trial of azathioprine in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

A controlled trial of azathioprine in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Double-blind trial of the use of transfer factor in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Neutrophil dysfunction in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Levamisole in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Oral BCG vaccine in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Disodium cromoglycate in the treatment of chronic proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Comparative trial of sulphasalazine and oral sodium cromoglycate in the maintenance of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Comparison of disodium cromoglycate and sulphasalazine as maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Control of Free Fatty Acids in Human Surface Lipids by Corynebacterium Acnes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

Metronidazole in Crohn's disease. A double blind cross-over clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

12C-glycocholate test in Crohn's disease its value in assessment and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

What can experimental colorectal cancer tell us about colorectal cancer in man?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03245.X

The role of intestinal bacteria in the metabolism of salicylazosulfapyridine

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

The treatment of ulcerative colitis

12 August 2023

7

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis

12 August 2023

8

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

12 August 2023

9

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

12 August 2023

12

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Maintenance of remission in ulcerative colitis with sulphasalazine or a high-fibre diet: a clinical trial

12 August 2023

18

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Medical Therapy of Inflammatory Bowel Disease

12 August 2023

31

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Maternal absorption and placental transfer of sulfasalazine

12 August 2023

33

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Hemolysis during salicylazosulfapyridine therapy

12 August 2023

37

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Sulphasalazine desensitisation.

12 August 2023

39

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Sulfasalazine-Induced Exacerbation of Ulcerative Colitis

12 August 2023

40

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas

12 August 2023

43

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis

12 August 2023

44

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Salicylazobenzoic acid in ulcerative colitis

12 August 2023

45

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

The pathogenesis and treatment of ulcerative colitis

12 August 2023

49

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Intensive treatment in severe acute attacks of ulcerative colitis

12 August 2023

62

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

ACTH and adrenalcorticosteroids in the treatment of ulcerative colitis

12 August 2023

64

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

The use of ACTH, cortisone, hydrocortisone and related compounds in the management of ulcerative colitis; experience in 180 patients

12 August 2023

65

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis

12 August 2023

70

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

On the absorption of prednisone and prednisolone disodium phosphate after rectal administration

12 August 2023

77

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION

12 August 2023

85

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients

12 August 2023

89

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

How should we treat Crohn's disease?

12 August 2023

97

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Controlled trial of azathioprine in Crohn's disease

12 August 2023

98

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

The azathioprine controversy: J.E. Lennard-Jones vs John W. Singleton

12 August 2023

102

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

12 August 2023

103

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Treatment Of Crohn’s Disease With Interferon A Preliminary Clinical Trial

12 August 2023

107

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

BCG treatment of Crohn's disease

12 August 2023

111

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Cromolyn sodium in the treatment of ulcerative colitis

12 August 2023

115

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Letter: Drug treatment in Crohn's disease

12 August 2023

126

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

Acquired hyperoxaluria with regional enteritis after ileal resection. Role of dietary oxalate

12 August 2023

132

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03245.X

12 August 2023

Identifiers

1 reference

17 September 2017

1 reference